ライフサイエンスコーパス: low-density lipoprotein

1 ion in response to its ligand, oxidized LDL (low-density lipoprotein).

2 M specific for malondialdehyde-modified LDL (low-density lipoprotein).

3 ed triglycerides (135-499 mg/dL), controlled low-density lipoprotein (41-100 mg/dL), and either estab

4 of atherosclerotic lesions probably requires low-density lipoprotein, a particle that carries cholest

5 response to sterile ligands such as oxidized low-density lipoprotein and damage-associated molecular

6 the AAPH-mediated oxidation of Caco-2 cells, low-density lipoprotein and deoxyribonucleic acid than t

7 e maternal circulation, maternal plasma very low-density lipoprotein and other lipoproteins are impor

8 tein B-containing lipoproteins, particularly low-density lipoprotein and remnant particles.

9 less high-density lipoprotein and more very-low-density lipoprotein and triglyceride particles in de

10 bolism, especially in the biogenesis of very low-density lipoproteins and chylomicrons via the transf

11 ipoprotein cholesterol, a surrogate for very-low-density lipoproteins and low-density lipoproteins, t

12 ody mass index, subcutaneous adipose tissue, low-density lipoproteins and total cholesterol levels).

13 both LDL-C and triglyceride (surrogates for low-density lipoproteins and very-low-density lipoprotei

14 lls, phagocytic activity, uptake of oxidized low-density lipoprotein, and cytokine expression.

15 PCSK9, low-density lipoprotein, and high-density lipoprotein co

16 Small increases in total cholesterol, low-density lipoprotein, and low-density lipoprotein par

17 ucing cardiovascular events, blood pressure, low-density lipoproteins, and adiposity-related outcomes

18 estinal fatty-acid binding protein, oxidized low-density lipoproteins, and soluble CD163 were measure

19 odies against oxidation-specific epitopes on low-density lipoprotein are anti-inflammatory and athero

20 nd fatty acid compartmentalization; and very low-density lipoprotein assembly and secretion.

21 Binding to lipids was observed in liposomes, low-density lipoproteins, cell membranes, and plasma.

22 high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total chol

23 ree potential risk factors for CAD including low density lipoprotein cholesterol (LDL-c), high densit

24 NR also did not elevate low density lipoprotein cholesterol or dysregulate 1-car

25 index; waist circumference; total, high and low density lipoprotein cholesterol; triglycerides; gluc

26 500 mg/dl (median baseline of 216 mg/dl) and low-density lipoprotein cholesterol >40 and <=100 mg/dl

27 fying triglycerides >=135 and <500 mg/dL and low-density lipoprotein cholesterol >40 and <=100 mg/dL

28 with triglycerides >150 but <=450 mg/dL and low-density lipoprotein cholesterol >=100 mg/dL (n=83 fo

29 s including diabetes mellitus, hypertension, low-density lipoprotein cholesterol >=100 mg/dl, and smo

30 es for secondary prevention in patients with low-density lipoprotein cholesterol >=70 mg/dL or non-hi

31 0%), systolic blood pressure <140 mm Hg, and low-density lipoprotein cholesterol <2.5 mmol/L were ass

32 .45) but was not significantly different for low-density lipoprotein cholesterol (0.04 mg/dL; 95% CI,

33 1% vs. 19% vs. 17%, respectively) and higher low-density lipoprotein cholesterol (117 vs. 107 vs. 103

34 with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) >=70 mg/dl o

35 us coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) <=70 mg/dl a

36 -1.07]; P = .42) but resulted in higher mean low-density lipoprotein cholesterol (LDL-c) (2.86 vs 2.6

37 examine the rates of statin utilization and low-density lipoprotein cholesterol (LDL-C) achieved 1-y

38 -1 (GLP-1) secretion were increased, and the low-density lipoprotein cholesterol (LDL-C) and blood ur

39 ic disorder, which causes elevated levels of low-density lipoprotein cholesterol (LDL-C) and increase

40 The relationship between exposure to lower low-density lipoprotein cholesterol (LDL-C) and lower sy

41 Mean changes in fasting low-density lipoprotein cholesterol (LDL-C) and non-high

42 LDL) secretion, and subsequently circulating low-density lipoprotein cholesterol (LDL-C) and triglyce

43 Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are heritabl

44 reased levels of total serum cholesterol and low-density lipoprotein cholesterol (LDL-C) at 6 months

45 dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 a

46 ular disease (CVD) increases with increasing low-density lipoprotein cholesterol (LDL-C) concentratio

47 opulations(3-5), despite having a lower mean low-density lipoprotein cholesterol (LDL-C) concentratio

48 to Target) showed the benefit of targeting a low-density lipoprotein cholesterol (LDL-C) concentratio

49 cholesterolemia (FH) who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals.

50 Low-density lipoprotein cholesterol (LDL-C) has been ass

51 Elevated low-density lipoprotein cholesterol (LDL-C) is associate

52 Low-density lipoprotein cholesterol (LDL-C) is causally

53 um-tolerated statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C) level >=70 m

54 s who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with a

55 LR), which in turn regulates the circulating low-density lipoprotein cholesterol (LDL-C) level.

56 h atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels >=70

57 scular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels.

58 type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels.

59 Although controlling low-density lipoprotein cholesterol (LDL-C) may improve

60 10 mg/dl [0.26 mmol/l]; p < 0.001), but not low-density lipoprotein cholesterol (LDL-C) or HDL-C, we

61 However, the presence of an elevated low-density lipoprotein cholesterol (LDL-C) polygenic ri

62 In this study, higher baseline levels of low-density lipoprotein cholesterol (LDL-C) predicted gr

63 atients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target level

64 Variants were weighted by associations with low-density lipoprotein cholesterol (LDL-C) using data f

65 density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measure

66 High-sensitivity CRP and low-density lipoprotein cholesterol (LDL-C) were measure

67 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

68 a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the tre

69 2 prior pregnancy losses; total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-densit

70 effects are weaker on women than on men, for low-density lipoprotein cholesterol (LDL-C), uric acid (

71 type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).

72 iglycerides to a greater extent than they do low-density lipoprotein cholesterol (LDL-C): fibrates, n

73 the percent change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary e

74 The main outcomes included low-density lipoprotein cholesterol (LDL-cholesterol), h

75 with or without ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactiv

76 ts of lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density

77 18.17%; 95% CI -21.14%, -15.19%; p < 0.001), low-density lipoprotein cholesterol (MD -22.94%; 95% CI

78 oprotein cholesterol (TRL-C) and small-dense low-density lipoprotein cholesterol (sdLDL-C) concentrat

79 rol, HDL-C, non-HDL-C, direct and calculated low-density lipoprotein cholesterol [LDL-C], and apolipo

80 Lifelong genetic exposure to lower levels of low-density lipoprotein cholesterol and lower systolic b

81 es more attention to percentage reduction in low-density lipoprotein cholesterol as a treatment goal

82 The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patie

83 ine or aspartate aminotransferase, total and low-density lipoprotein cholesterol at baseline (<0.05),

84 re genome-wide significantly associated with low-density lipoprotein cholesterol based on 3203 subjec

85 of all individuals to <130 mm Hg or lowering low-density lipoprotein cholesterol by 30% would be expe

86 urrent average levels with elevated total or low-density lipoprotein cholesterol concentrations.

87 -0.020 to -0.010] per year), mean levels of low-density lipoprotein cholesterol declined from 92 mg/

88 crucial areas: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional t

89 cholesterol, whereas EPA-only did not raise low-density lipoprotein cholesterol in very high triglyc

90 l <6.2%, systolic blood pressure <120 mm Hg, low-density lipoprotein cholesterol level <2.0 mmol/L [<

91 that intensive lipid-lowering therapy (to a low-density lipoprotein cholesterol level of <70 mg/dl)

92 adults with a recent first MI and a baseline low-density lipoprotein cholesterol level of 1.81 mmol/L

93 eciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 m

94 The low-density lipoprotein cholesterol level was lower by a

95 e subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovas

96 There was no relation between baseline low-density lipoprotein cholesterol levels and magnitude

97 ases in total, high-density lipoprotein, and low-density lipoprotein cholesterol levels compared with

98 ter high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels were associat

99 ns in continuous measures of blood pressure, low-density lipoprotein cholesterol levels, fasting gluc

100 Additional risk factors for CVD include low-density lipoprotein cholesterol levels, hypertension

101 been found to lower blood pressure (BP) and low-density lipoprotein cholesterol levels.

102 iated with a higher concentration of smaller low-density lipoprotein cholesterol particles.

103 lycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol than contemporary gu

104 entrations of triglyceride and low- and very-low-density lipoprotein cholesterol than controls, sugge

105 Recipient mice all had low levels of low-density lipoprotein cholesterol to promote plaque re

106 Mean estimated untreated low-density lipoprotein cholesterol was 206 mg/dL in tho

107 per 1% glycohemoglobin difference), whereas low-density lipoprotein cholesterol was associated with

108 , fasting plasma triglycerides and high- and low-density lipoprotein cholesterol were measured in 34

109 , decades of research has established LDL-C (low-density lipoprotein cholesterol) as a causal factor

110 signaling plays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through

111 whelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovas

112 icacy and safety of markedly lowering LDL-C (low-density lipoprotein cholesterol).

113 lipoprotein(a) is associated with increased low-density lipoprotein cholesterol, a family history of

114 LDL influence atherogenesis independently of low-density lipoprotein cholesterol, and high sensitivit

115 were adjusted for traditional risk factors, low-density lipoprotein cholesterol, and high-sensitivit

116 ted with higher blood HDL cholesterol, lower low-density lipoprotein cholesterol, and lower risk of c

117 predictors of meeting trial goals for LDL-C (low-density lipoprotein cholesterol, goal <70 mg/dL) or

118 ss index, comorbidities and their treatment, low-density lipoprotein cholesterol, liver biochemistrie

119 e and after 1 year: systolic blood pressure, low-density lipoprotein cholesterol, nonsmoking, physica

120 ucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pres

121 A, suggesting that therapeutic modulation of low-density lipoprotein cholesterol, the lipoprotein lip

122 Higher levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides, digl

123 erides by >=30% with concurrent increases in low-density lipoprotein cholesterol, whereas EPA-only di

124 tergenic region near APOC1P1 associated with low-density lipoprotein cholesterol.

125 lycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol.

126 e 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol.

127 ished cardiovascular disease irrespective of low-density lipoprotein cholesterol.

128 betes mellitus, systolic blood pressure, and low-density lipoprotein cholesterol.

129 ed candidate causal genes for schizophrenia, low-density-lipoprotein cholesterol and Crohn's disease.

130 The concentrations of high- and low-density-lipoprotein cholesterol and triglycerides ar

131 igh polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyce

132 Reductions from baseline in LDL (low-density lipoprotein) cholesterol and Lp(a) (lipoprot

133 levation of aminotransferases, elevation of (low-density lipoprotein) cholesterol and steatosis in he

134 Pericardial fat volumes and LDL (low-density lipoprotein) cholesterol concentrations corr

135 has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and

136 2 have decreased ABCA1 expression, increased low-density lipoprotein-cholesterol (LDL-C) and choleste

137 nt weight reduction and improved small dense low-density lipoprotein-cholesterol (sdLDL-C) profiles,

138 inding raises the possibility that increased low-density lipoprotein clearance (the effect of these P

139 These mutations result in accumulation of low-density lipoprotein-derived cholesterol in late endo

140 siological shear stress with enzyme-modified low-density-lipoprotein (eLDL) with or without TNFalpha

141 varied between 0.09% (ALT) and 18.49% (LDL [low-density lipoprotein]) for the other traits.

142 an add-on to a statin for patients reaching low-density lipoprotein goal but with persistent moderat

143 mature IHD, and severe hypercholesterolemia (low-density lipoprotein >=190 mg/dl), overall prevalence

144 stolic and diastolic blood pressures, pulse, low-density lipoprotein, high-density lipoprotein, trigl

145 ated fatty acid intake (%SFA) and changes in low-density lipoproteins, high-density lipoproteins, and

146 e, including increases in total cholesterol, low-density lipoproteins, high-density lipoproteins, pho

147 sterol dysregulation, generation of oxidized low-density lipoprotein, increased recruitment of hepati

148 , the increased concentration of circulating low-density lipoprotein, is also involved in inflammatio

149 poprotein B(100) (apoB), the core protein of low-density lipoprotein, is an autoantigen that drives t

150 ugh uptake of extracellular cholesterol from low density lipoproteins (LDL) via expression of LDL rec

151 tein (HDL) <40 mg/dL, 2,078 subjects (5.3%); low-density lipoprotein (LDL) >130 mg/dL, 2,756 subjects

152 fe, and imputed risk factor trajectories for low-density lipoprotein (LDL) and high-density lipoprote

153 evaluate the impact of small dense (sdLDL-C) low-density lipoprotein (LDL) cholesterol (LDL-C) on CVD

154 mia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increas

155 This study investigated whether higher low-density lipoprotein (LDL) cholesterol and triglyceri

156 ffects of the intervention on SFA intake and low-density lipoprotein (LDL) cholesterol as well as the

157 Reduced low-density lipoprotein (LDL) cholesterol due to inhibit

158 in HMGCR, NPC1L1, and PCSK9 associated with low-density lipoprotein (LDL) cholesterol in a genome-wi

159 e is intimately linked to elevated levels of low-density lipoprotein (LDL) cholesterol in the blood.

160 on and stroke(1), is initiated by passage of low-density lipoprotein (LDL) cholesterol into the arter

161 from baseline in systolic blood pressure and low-density lipoprotein (LDL) cholesterol level at 12 mo

162 as the same effect, per unit decrease in the low-density lipoprotein (LDL) cholesterol level, as the

163 inal fat, high total cholesterol level, high low-density lipoprotein (LDL) cholesterol level, high ve

164 olemia is characterized by severely elevated low-density lipoprotein (LDL) cholesterol levels and pre

165 dies point to an inverse correlation between low-density lipoprotein (LDL) cholesterol levels and ris

166 fractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite

167 isiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with in

168 liver as a central regulator of circulating low-density lipoprotein (LDL) cholesterol levels, a know

169 d in the SWAI population and associated with low-density lipoprotein (LDL) cholesterol levels.

170 9, is widely used in adult patients to lower low-density lipoprotein (LDL) cholesterol levels.

171 ood pressure (SBP) of at least 140 mm Hg, or low-density lipoprotein (LDL) cholesterol of at least 13

172 ls have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in few

173 BMI, -0.13 kg/m2 (-0.75 to 0.09), p = 0.093; low-density lipoprotein (LDL) cholesterol, 0.06 mmol/L (

174 Although SFAs increase low-density lipoprotein (LDL) cholesterol, in most indiv

175 in lipid traits in the UK Biobank (UKBB) for low-density lipoprotein (LDL) cholesterol, triglycerides

176 isease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol.

177 saturated fatty acid (SFA) content to raise low-density lipoprotein (LDL) cholesterol.

178 itor of ATP citrate lyase, reduces levels of low-density lipoprotein (LDL) cholesterol.

179 risk, but confusion surrounds its effects on low-density lipoprotein (LDL) cholesterol.

180 tified ALK-1 as a high-capacity receptor for low-density lipoprotein (LDL) in endothelial cells that

181 Low-density lipoprotein (LDL) is heterogeneous, composed

182 Low-density lipoprotein (LDL) metabolism was studied in

183 btilisin/kexin type-9 (PCSK9) is a ligand of low-density lipoprotein (LDL) receptor (LDLR) that promo

184 the parent peptide and efficiently restored low-density lipoprotein (LDL) receptor levels and cleare

185 I-1) with its target enzymes bind tightly to low-density lipoprotein (LDL) receptor-related protein 1

186 comes in chronic hepatitis C (CHC) patients: low-density lipoprotein (LDL), high-density lipoprotein,

187 raits that include high-density lipoprotein, low-density lipoprotein (LDL), total cholesterol and tri

188 cholesterol from receptor-mediated uptake of low-density lipoprotein (LDL), which releases cholestero

189 and spontaneously associate with circulating low-density lipoprotein (LDL), while less lipophilic lip

190 ociations for cholesterol were strongest for low-density lipoprotein (LDL)-cholesterol, and remained

191 es from intestinal cells to the germline via low-density lipoprotein (LDL)-like particles to promote

192 (a)) covalently bound to apolipoprotein B of low-density lipoprotein (LDL).

193 Lowering low-density lipoprotein (LDL-C) and triglyceride (TG) le

194 Increased first-trimester low-density lipoprotein (LDL-C) concentration has been a

195 :p.K405X, which is associated with decreased low-density-lipoprotein (LDL) cholesterol (P = 1.3 x 10(

196 the plasma membrane where they bind modified low-density-lipoprotein (LDL) cholesterol as normal.

197 ces (TMs) and three lumenal domains, exports low-density-lipoprotein (LDL)-derived cholesterol from l

198 [OR] per one standard deviation decrease in low-density lipoprotein [LDL] cholesterol 0.76, 95% conf

199 years; 35% women; 70% with diabetes; median low-density lipoprotein [LDL] cholesterol level, 75.0 mg

200 lipid traits (high-density lipoprotein, HDL; low-density lipoprotein, LDL; triglycerides, TGs) with r

201 Low-density lipoproteins (LDLs) are removed by extracorp

202 ntermediate-density lipoproteins (IDLs), and low-density lipoproteins (LDLs).

203 aminases, fasting blood sugar, triglyceride, low density lipoprotein level, and lower high density li

204 of diabetes, high-density lipoprotein level, low-density lipoprotein level, history of hypertension,

205 Low low-density lipoprotein levels are associated with incre

206 Whether low low-density lipoprotein levels contribute causally to ad

207 n associated with increased mortality if low low-density lipoprotein levels contributed causally to s

208 re genotyped, and a genetic score related to low-density lipoprotein levels was calculated.

209 de polymorphisms known to be associated with low-density lipoprotein levels were genotyped, and a gen

210 c score, known to be directly related to low low-density lipoprotein levels, was associated with decr

211 Lipoprotein(a) is an atherogenic low-density lipoprotein-like particle and circulating le

212 recently exemplified by association of LDL (low-density lipoprotein)-lowering variants in the HMGCR

213 knowledge, icosapent ethyl is the first non-low-density lipoprotein-lowering treatment that has been

214 sin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein metabolism, is induced by leptin

215 CD69 binding to oxidized low-density lipoprotein on T cells induces the expressio

216 eater intracellular gaps and permeability to low-density lipoprotein or transmigrating THP-1 cells.

217 or changes in blood concentrations of total, low-density lipoprotein, or high-density lipoprotein cho

218 vity C-reactive protein (HsCRP) and oxidized low-density lipoprotein (Ox-LDL) in adolescents.

219 iation and progression by taking up oxidized low-density lipoprotein (oxLDL) and promoting inflammato

220 ion, followed by measurement of labeled very low-density lipoprotein palmitate via gas chromatography

221 22.94%; 95% CI -26.63%, -19.25%; p < 0.001), low-density lipoprotein particle number (MD -20.67%; 95%

222 .51%; 95% CI -3.75%, 0.74%; p = 0.189), very-low-density lipoprotein particle number (MD 3.79%; 95% C

223 Low-density lipoprotein particle size and high-density l

224 Exported very-low density lipoprotein particles were isolated for unta

225 Low-density lipoprotein particles are taken up by cells

226 al cholesterol, low-density lipoprotein, and low-density lipoprotein particles, but no changes in mar

227 Early studies established that LDL (low-density lipoprotein) particles could act as efficien

228 f murine and human macrophages with oxidized low-density lipoprotein recapitulated some of the transc

229 The apoE receptors low-density lipoprotein receptor (LDLR) and LDLR-related

230 a dramatic reduction in transcript levels of low-density lipoprotein receptor (LDLR) and of keratin g

231 fied sulfated glycosaminoglycans (sGAGs) and low-density lipoprotein receptor (LDLR) as host factors

232 Hepatic abundance of the low-density lipoprotein receptor (LDLR) is a critical de

233 btilisin/kexin type 9 (PCSK9), which reduces low-density lipoprotein receptor (LDLR) recycling and he

234 sponsible for the degradation of the hepatic low-density lipoprotein receptor (LDLR), which in turn r

235 Low-density lipoprotein receptor (Ldlr)-knockout mice we

236 transforming growth factor beta 1, oxidized low-density lipoprotein receptor 1, and C-C motif chemok

237 screen identified cholesterol uptake by the low-density lipoprotein receptor as essential for the gr

238 atp-binding cassette transporter (atp), and low-density lipoprotein receptor chaperone (ldlr), that

239 e-wide CRISPR-Cas9-based screen, we identify low-density lipoprotein receptor class A domain-containi

240 Five-week-old female low-density lipoprotein receptor deficient (LDL-R-/-) an

241 bred onto both the Apoe(-/-) and Ldlr(-/-) (low-density lipoprotein receptor deficient) knockout str

242 s a result of lower hepatic mRNA editing and low-density lipoprotein receptor expression, and higher

243 -2) is a protein structurally related to the low-density lipoprotein receptor family that displays a

244 Genetic ablation of Idol increases low-density lipoprotein receptor protein levels, which f

245 Moreover, LDLR (low-density lipoprotein receptor) deficient animals tran

246 lted in upregulation (~1.5 fold) of oxidized low-density lipoprotein receptor-1 (LOX-1).

247 rom male Flna (o/fl)/ LC mice to atherogenic low-density lipoprotein receptor-deficient ( Ldlr(-/-))

248 Low-density lipoprotein receptor-deficient chimeric mice

249 ions in atherosclerotic aortas obtained from low-density lipoprotein receptor-deficient mice.

250 We found that an extracellular fragment of low-density lipoprotein receptor-related protein 1 (LRP-

251 g internalization of a SNX17 cargo receptor, low-density lipoprotein receptor-related protein 1 (LRP1

252 Here we show that the low-density lipoprotein receptor-related protein 1 (LRP1

253 We hypothesized that LRP1 (low-density lipoprotein receptor-related protein 1) expr

254 inding of y+z+ agrin to both heparin and the low-density lipoprotein receptor-related protein 4 (LRP4

255 Low-density lipoprotein receptor-related protein 4 (Lrp4

256 s anti-osteoanabolic activity is enhanced by low-density lipoprotein receptor-related protein 4 (Lrp4

257 We demonstrate that the low-density lipoprotein receptor-related protein 4 (LRP4

258 We explored the role of low-density lipoprotein receptor-related protein 4 (LRP4

259 spectroscopy and show that the co-receptor, low-density lipoprotein receptor-related protein 5 (Lrp5

260 ated the conditional knockout Wnt coreceptor low-density lipoprotein receptor-related protein 5 (Lrp5

261 nt signaling, we observed elevated levels of low-density lipoprotein receptor-related protein 5/6 (LR

262 Low-density lipoprotein receptor-related protein 6 (LRP6

263 rotein receptor-related protein 5 (Lrp5) and low-density lipoprotein receptor-related protein 6 (Lrp6

264 s duplication in Xenopus embryos, stimulated low-density lipoprotein receptor-related protein 6 (LRP6

265 Low-density lipoprotein receptor-related protein 6 encod

266 Reduction of frizzleds (fz), arrow (low-density lipoprotein receptor-related protein [LRP] 5

267 have been reported to be endocytosed by the low-density lipoprotein receptor-related protein-1 (LRP-

268 e N-methyl-d-aspartate receptor (NMDA-R) and low-density lipoprotein receptor-related protein-1 (LRP1

269 n neutrophils and monocytes to MDSCs via the low-density lipoprotein receptor-related protein-2 (LRP2

270 metabolism and insulin sensitivity through a low-density lipoprotein receptor-related protein-2 (LRP2

271 ucing liver-specific degradation of the LDL (low-density lipoprotein) receptor combined with a 10-wee

272 Loss-of-function mutations in the LDL (low-density lipoprotein) receptor gene (LDLR) cause elev

273 Eight-week-old male low-density-lipoprotein-receptor-deficient mice were sub

274 PCSK9, which promotes the degradation of low-density lipoprotein receptors and, therefore, the in

275 ogates for low-density lipoproteins and very-low-density lipoproteins, respectively), the RR was 0.80

276 lipoprotein E, lipoprotein(a), oxidized LDL (low density lipoprotein)'s and large LDL particles, as w

277 eride-rich lipoprotein (TRL) and small-dense low-density lipoprotein (sdLDL) particles are hallmarks

278 The proinflammatory cytokines and oxidized low-density lipoprotein significantly increased in the p

279 r increases of most components of VLDL (very low density lipoprotein) subparticles.

280 LDL (low-density lipoprotein) that has accumulated in the art

281 rogate for very-low-density lipoproteins and low-density lipoproteins, the RR per 1-mmol/L reduction

282 ke pattern, characterized by a high ratio of low-density lipoprotein to high-density lipoprotein, and

283 roduction of NO and reduced inflammation and low-density lipoprotein trafficking.

284 that the absence of Cav1/caveolae inhibited low-density lipoprotein transport across the endothelium

285 nd women and measuring the synthesis of very low-density lipoprotein triglyceride (VLDL-TG) palmitate

286 cies (ROS) levels, caspase 3/7 activity, and low-density lipoprotein uptake, activation of oxidative

287 n, cellular adhesion, phagocytosis, oxidized low-density lipoprotein uptake, and expression of inflam

288 lated with the immune system, including very-low-density lipoprotein, vitellogenin, estrogen receptor

289 ements, hepatic metabolite analysis and very low density lipoprotein (VLDL)-TG secretion assays revea

290 poprotein (LDL) cholesterol level, high very low-density lipoprotein (VLDL) cholesterol level, high t

291 ss, and adipocyte cell size and reduced very low-density lipoprotein (VLDL) levels, as compared with

292 ing pathway, thereby regulating hepatic very low-density lipoprotein (VLDL) secretion, and subsequent

293 itochondrial oxidation and secretion as very low-density lipoprotein (VLDL) triglycerides.

294 HDL) subclasses and decreased levels of very low-density lipoprotein (VLDL), amino acids, and citrate

295 needed for lipoprotein synthesis, e.g., very low-density lipoprotein (VLDL), the precursor of circula

296 eride (TAG)-rich lipoproteins including very low density lipoproteins (VLDLs) and chylomicrons, and r

297 rol and triglycerides, respectively, in very low-density lipoproteins (VLDLs).

298 ude the total level of cholesterol and high-/low-density lipoproteins, which often fails to accuratel

299 fish, red meat yielded greater decreases in low-density lipoprotein (WMD, -0.173 mmol/L; 95% CI, -0.

300 64 mmol/L; 95% CI, 0.144-0.383; P<0.001) and low-density lipoprotein (WMD, 0.198 mmol/L; 95% CI, 0.06